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BACKGROUND: Arrhythmogenic cardiomyopathy (ACM) is an inherited 
heart muscle disorder characterized by myocardial fibrofatty replacement 
and an increased risk of sudden cardiac death (SCD). Originally described as 
a right ventricular disease, ACM is increasingly recognized as a biventricular 
entity. We evaluated pathological, genetic, and clinical associations in a large 
SCD cohort.
METHODS: We investigated 5205 consecutive cases of SCD referred 
to a national cardiac pathology center between 1994 and 2018. Hearts 
and tissue blocks were examined by expert cardiac pathologists. After 
comprehensive histological evaluation, 202 cases (4%) were diagnosed 
with ACM. Of these, 15 (7%) were diagnosed antemortem with dilated 
cardiomyopathy (n=8) or ACM (n=7). Previous symptoms, medical history, 
circumstances of death, and participation in competitive sport were 
recorded. Postmortem genetic testing was undertaken in 24 of 202 (12%). 
Rare genetic variants were classified according to American College of 
Medical Genetics and Genomics criteria.
RESULTS: Of 202 ACM decedents (35.4±13.2 years; 82% male), no 
previous cardiac symptoms were reported in 157 (78%). Forty-one 
decedents (41/202; 20%) had been participants in competitive sport. 
The adjusted odds of dying during physical exertion were higher in 
men than in women (odds ratio, 4.58; 95% CI, 1.54–13.68; P=0.006) 
and in competitive athletes in comparison with nonathletes (odds ratio, 
16.62; 95% CI, 5.39–51.24; P<0.001). None of the decedents with an 
antemortem diagnosis of dilated cardiomyopathy fulfilled definite 2010 Task 
Force criteria. The macroscopic appearance of the heart was normal in 40 
of 202 (20%) cases. There was left ventricular histopathologic involvement 
in 176 of 202 (87%). Isolated right ventricular disease was seen in 13%, 
isolated left ventricular disease in 17%, and biventricular involvement 
in 70%. Among whole hearts, the most common areas of fibrofatty 
infiltration were the left ventricular posterobasal (68%) and anterolateral 
walls (58%). Postmortem genetic testing yielded pathogenic variants in 
ACM-related genes in 6 of 24 (25%) decedents.
CONCLUSIONS: SCD attributable to ACM affects men predominantly, most 
commonly occurring during exertion in athletic individuals in the absence of 
previous reported cardiac symptoms. Left ventricular involvement is observed 
in the vast majority of SCD cases diagnosed with ACM at autopsy. Current 
Task Force criteria may fail to diagnose biventricular ACM before death.
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Arrhythmogenic cardiomyopathy (ACM) is a ge-netic heart muscle disorder characterized by myocardial atrophy and fibrofatty replacement 
of the ventricular myocardium. Originally described as 
arrhythmogenic right ventricular cardiomyopathy/dys-
plasia,1,2 increased recognition of left ventricular (LV) 
involvement has recently led to adoption of the term 
ACM.3,4 ACM has an estimated prevalence of 1:2000 
to 1:5000 and is an important cause of sudden cardiac 
death (SCD) among young individuals, including ath-
letes.3,5,6 ACM typically follows a Mendelian autosomal 
dominant inheritance pattern, where disease-causing 
mutations in >13 genes have been identified.7 Approxi-
mately half of the index cases with a clinical diagnosis 
harbor putative mutations in genes encoding desmo-
somal proteins: PKP2 (plakophilin-2), DSP (desmopla-
kin), DSC2 (desmocollin-2), JUP (junction plakoglobin), 
and DSG2 (desmoglein-2).
Clinical presentation of ACM is heterogeneous, 
and diagnosis can be challenging.3 This is reflected by 
the Task Force criteria, which integrate a number of 
structural, histopathologic, electrocardiographic, fa-
milial, arrhythmic, and genetic parameters.6 Moreover, 
these criteria are derived from cohorts with predomi-
nantly right ventricular involvement (arrhythmogenic 
right ventricular cardiomyopathy/dysplasia), and thus 
can potentially fall short for a significant proportion 
of those with LV dominant or biventricular disease. 
Task Force criteria require the presence of fibrofatty 
replacement of the right ventricular (RV) free wall 
myocardium on endomyocardial biopsy or at autop-
sy6; however, pathological and imaging studies have 
reported LV involvement ranging between 16% and 
76% of cases.8–12 Cardiovascular magnetic resonance 
(CMR) may show late gadolinium enhancement, indic-
ative of myocardial fibrosis, in a subepicardial or mid-
myocardial distribution, usually within the LV inferior 
or inferolateral walls.13
The purpose of this study was to report the patho-
logical features of a large cohort of decedents that had 
experienced SCD from ACM, with a particular focus on 
the presence of LV involvement. In addition, we sought 
to report on the clinical characteristics and genetic as-
sociations of the cohort.
METHODS
The data, analytical methods, and study materials will not be 
made available to other researchers for purposes of reproduc-
ing the results or replicating the procedure. All unexpected 
sudden deaths in the United Kingdom are reported to the 
coroner, who determines the need for autopsy examination. 
The Cardiac Risk in the Young Center for Cardiac Pathology 
at St George’s, University of London, provides a nationally rec-
ognized expert cardiac pathology service. Referral is initiated 
voluntarily by the coroner’s pathologist after an unexplained 
SCD, or if there is suspicion of an inherited heart condition. 
The center receives ≈500 SCD cases per annum, just over half 
under the age of 35 years. A report to the coroner is issued 
within a 2-week period.
All referrals to the Cardiac Risk in the Young Center 
for Cardiac Pathology undergo a full coroner’s pathologist 
autopsy. Since 2013, spleen samples have been collected for 
postmortem genetic testing. Pathological findings and cor-
responding clinical information were entered into a database 
incorporating imaging from histological sections and autopsy/
toxicology reports from UK coroners. Ethical approval for this 
study was obtained from the UK National Health Service 
Research Ethics Committee. Informed consent was provided 
by the next of kin at the time of referral.
Study Group
We evaluated 5205 consecutive SCD cases referred to the 
Cardiac Risk in the Young Center for Cardiac Pathology 
between 1994 and 2018 (Figure  1). Inclusion criteria for 
this study were: (1) SCD defined by one of the following: 
an unheralded witnessed instantaneous death, a death pre-
ceded by a prodrome of acute cardiac symptoms up to 1 
hour before death, or an unwitnessed case without a pre-
vious deterioration in the preceding 24 hours; (2) patho-
logical diagnosis of ACM at autopsy; (3) absence of an 
extracardiac cause of death; (4) negative toxicology screen; 
and (5) absence of obstructive coronary artery disease 
(atherosclerosis with residual luminal diameter <1mm2). 
Decedents with an antemortem diagnosis of cardiomyopa-
thy were included.
Clinical Perspective
What Is New?
• In this large comprehensive autopsy study, we 
demonstrate that left ventricular involvement is 
observed in most decedents with arrhythmogenic 
cardiomyopathy and the left ventricle is exclusively 
involved in nearly a fifth of cases.
• Age at death, sex, normal macroscopic appearance 
of the heart, and participation in competitive sport 
were not associated with the presence of left ven-
tricular involvement.
• We describe diagnostic histopathologic criteria for 
arrhythmogenic cardiomyopathy involving either or 
both ventricles.
What Are the Clinical Implications?
• This study identified that the heart was macroscop-
ically normal in 20% of decedents with arrhyth-
mogenic cardiomyopathy; expert pathological 
assessment, including histology, is therefore crucial 
to inform diagnosis in cases of initially unexplained 
sudden cardiac death.
• Left ventricular variants of arrhythmogenic cardio-
myopathy may evade clinical detection using cur-
rent diagnostic tools; this should be addressed in 
future revisions of Task Force criteria.
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Demographics and Clinical Characteristics
A questionnaire was sent to all referring pathologists and 
coroners’ officers relating to demographics, medical history, 
symptoms, family history, sports participation, and circum-
stances of death. Additional information was obtained by 
autopsy reports from the referring pathologist, primary care/
hospital correspondence, and family member interviews. This 
was acquired within 3 months of initial referral to our center. 
Media and sports club correspondence was also reviewed for 
competitive sports participation. Decedents were considered 
competitive athletes if they had engaged in an organized 
team or individual sport requiring regular training and partici-
pation in competitive events.14 For those with an antemortem 
diagnosis of cardiomyopathy, the clinical notes and investiga-
tions (including ECG, echocardiography, ambulatory cardiac 
monitoring, signal-averaged ECG, and CMR) were subse-
quently requested and analyzed according to the revised Task 
Force criteria.6
Autopsy Evaluation
Whole hearts (3018/5205; 58%) and cases with tissue 
blocks (2187/5205; 42%) underwent detailed histopatho-
logic analysis, including microscopic examination of tis-
sue from both ventricles. Sections were fixed in formalin, 
embedded in paraffin, and stained with hematoxylin and 
eosin. The following areas were routinely examined: the 
right ventricular outflow tract; the anterior, lateral, and pos-
terior right ventricle (midventricular level); interventricular 
septum; anterior, lateral and posterior left ventricle; the 3 
major coronary arteries; and the ascending aorta. The apices 
of both ventricles were not examined in the absence of an 
overt structural abnormality. Information from the referring 
pathologist’s autopsy was also recorded, incorporating mac-
roscopic appearances of the heart, body weight, and heart 
weight. At least 2 tissue blocks from both ventricles were 
required for study inclusion.
ACM was defined on microscopic analysis as myocyte 
degeneration associated with intermixed fat and fibro-
sis (within the same microscopic field) from the subepicar-
dial region inward or transmural in either or both ventricles 
(>20% in at least 2 tissue blocks of 4 cm2; hematoxylin and 
eosin stain). Disease involvement within the interventricular 
septum was defined by myocyte degeneration associated 
with intermixed fat and fibrosis from either side or within the 
midwall. This definition has been updated from a previous 
report.15 Figure 2 compares normal histological appearances 
in the right ventricle with a case meeting diagnostic criteria 
for ACM. All cases included in the study were examined by 
the senior author (M.N.S.), in addition to review by at least 
one other pathologist.
Postmortem Genetic Testing
After extraction of DNA from retained splenic tissue (n=24), 
cardiac gene panel testing was performed using the Illumina 
TruSight Cardio (174 genes) panel (or a custom Agilent 
SureSelect with equivalent content; Table I in the online-
only Data Supplement) and sequenced on the Illumina 
platform (NextSeq or HiSeq), as previously described and 
validated.16,17 Variant annotation was then undertaken in-
house using SnpEff v4.3T (build 2017-11-24),18 GRCh37.75, 
and ANNOVAR (version 2017-07-17).19 Rare variants were 
defined as those with a minor allele frequency cutoff <0.01% 
in the Exome Aggregation Consortium general population 
database (http://exac.broadinstitute.org). Rare variants were 
then assessed for pathogenicity according to the American 
College of Medical Genetics and Genomics criteria.20 These 
criteria integrate a number of factors including population 
data, functional data, computational data, and segregation 
analysis to inform assessment of pathogenicity.
Statistical Analysis
All variables were graphically inspected and summarized 
according to their nature and by outcomes of interest (ie, 
mean, SD, median) for continuous variables and proportions for 
binary or categorical variables. Data are presented as mean±1 
SD or percentages and appropriate tests (t tests, [Fisher] χ2) 
were used for a preliminary flavor of variable associations.
There were 2 outcomes of primary interest, notably death 
occurring during physical exertion and LV histopathologic 
involvement. Univariable and multivariable logistic regression 
analyses were used to understand the strength of the crude 
and adjusted associations between these 2 outcomes and 
available demographics and clinical features in the ACM SCD 
group. The Hosmer-Lemeshow test was used to assess models’ 
goodness of fit. A P value of <0.05 was deemed statistically 
significant. Statistical analyses were performed using Stata 
IC/15 (StataCorp). The author (I.C.S.) holds responsibility for 
the statistical methodology applied to the data in this article.
RESULTS
Baseline Demographics
Of 5205 cases of SCD referred to our unit, 202 (4%) 
were diagnosed with ACM. The majority of decedents 
Figure 1. Selection of ACM cases from all SCD referred to pathology 
center. 
ACM indicates arrhythmogenic cardiomyopathy; and SCD, sudden cardiac death.
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from ACM were male (166/202; 82%) and white 
(182/202; 90%). The mean age of death was 35.4±13.2 
years (median, 34.5 years).
Clinical Characteristics
The great majority of cases (187/202; 93%) did not 
have an antemortem diagnosis of cardiac disease. Only 
15 of 202 (7%) decedents carried a diagnosis of car-
diomyopathy, of which 7 of 15 (47%) were labeled as 
ACM and 8 of 15 (53%) were labeled as dilated car-
diomyopathy (DCM). Six of the overall SCD cohort with 
ACM (6/202; 3%) had an implantable cardioverter de-
fibrillator in situ. Fifteen (7%) reported a family history 
of SCD under the age of 35 years, none of whom were 
diagnosed with cardiomyopathy in life. Two decedents 
with a positive family history had been referred for clini-
cal investigation. Table 1 outlines clinical and pathologi-
cal characteristics stratified by circumstances of death.
In most decedents with ACM (157/202; 78%), there 
were no reported symptoms before death; there were 
20 (10%) instances of syncope recorded before death, 
which was associated with an antemortem diagnosis of 
cardiomyopathy in 6 cases. The remaining decedents 
(25/202; 12%) had a documented history of palpita-
tions (8%), chest pain (2%), and presyncope (2%). 
Eighty-three (41%) of the overall cohort died during 
physical exertion, and 105 (52%) died at rest or during 
sleep. Decedents with an existing diagnosis of cardio-
myopathy were more likely to have died at rest or dur-
ing sleep in comparison with during physical exertion 
(87% versus 7%, respectively; P=0.004). Circumstances 
of death were unspecified in 14 of 202 (7%); there was 
no significant pattern in missing data with respect to 
other variables. Among young (<35 years old) dece-
dents with ACM, there were more deaths during physi-
cal exertion than among older decedents (50% versus 
33%, respectively; P=0.01).
Pathological Characteristics
In the majority of cases (120/202; 59%), the whole 
heart was received for analysis. Of the remaining cases 
with tissue blocks (41%), the mean number of blocks 
received across both ventricles was 8.3±3.2 (range 4–
15). In 40 of 202 (20%), macroscopic examination of 
the heart did not yield an overt structural abnormal-
ity (Figure I in the online-only Data Supplement). Heart 
weight and body weight were recorded in 193 of 202 
(96%) and 131 of 202 (65%) cases, respectively, and 
demonstrated a positive correlation (r=0.55, P<0.001, 
n=129). Overall, 27% of men recorded heart weights 
>500 g, and 23% of women recorded heart weights 
>400g. The association between body weight and 
Figure 2. Histological examination of ACM: 
normal findings within the RV vs patho-
logical criteria for ACM. 
ACM indicates arrhythmogenic cardiomyopa-
thy; and RV, right ventricle.
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heart weight was independent of LV histopathologic 
involvement (n=129, P=0.74). After histological evalu-
ation, none of the cases meeting diagnostic criteria for 
ACM showed myocardial inflammatory infiltrates.
Ventricular Involvement
An overview of ventricular histopathologic involvement 
is presented in Figure  3. LV fibrofatty infiltration was 
present in 176 of 202 (87%) decedents. Disease exclu-
sive to the LV was observed in 35 of 202 (17%), and RV 
in 26 of 202 (13%), with 141 of 202 (70%) having evi-
dence of biventricular disease. Among whole hearts re-
ferred to our center (120/202; 59%), the most common 
sites of LV disease involvement were the posterobasal 
wall (81/120; 68%) and anterolateral wall (69/120; 
58%). In the RV, the anterolateral wall (77/120; 64%) 
and RV outflow tract (57/120; 48%) were most fre-
quently implicated. A logistic regression model found 
no significant association between LV disease and age 
at death (P=0.31), male sex (P=0.58), macroscopically 
normal appearance of the heart (P=0.49), or competi-
tive sport participation (P=0.27; Table II in the online-
only Data Supplement).
Competitive Athletes
Of 202 decedents with ACM, 41 (20%) had partici-
pated in competitive sport and the majority of the de-
cedents (35/41; 85%) were aged <35 years. Thirty-one 
athletes (31/41; 76%) had been engaged in sports with 
a high dynamic component (Figure II in the online-only 
Data Supplement). The vast majority (37/41; 90%) of 
athletes died during physical exertion, including 30 
athletes (30/41; 73%) who died during participation in 
sport. In contrast, 46 of 147 (31%) of the nonathlete 
decedents died during physical exertion (90% versus 
31%, respectively; P<0.001). There was no significant 
difference in disease distribution within the heart be-
tween athletes and nonathletes (P=0.10).
Multivariable analysis showed that male sex (odds 
ratio, 4.58; 95% CI, 1.54–13.68; P=0.006) and partici-
pation in competitive sport (odds ratio, 16.62; 95% CI, 
5.39–51.24; P<0.001) were independent predictors of 
death during physical exertion (Table 2).
Genetic Testing
Genetic testing was performed in all cases with post-
mortem DNA available (n= 24 [12%]). A total of 27 
rare variants were identified in 14 of 24 (58%) cases. 
Six decedents (6/24; 25%) hosted single pathogenic 
variants in known ACM genes: DSP (n=2; truncating 
mutations), TMEM43 (n=2; missense mutations), and 
PKP2 (n=2; frameshift mutations; Table  3). The same 
pathogenic TMEM43 variant (p.Ser358Leu) was identi-
fied in 2 unrelated individuals and has been described 
in a number of different cohorts in the ClinVar data-
base (https://www.ncbi.nlm.nih.gov/clinvar). None of 
the decedents hosted >1 pathogenic variant. Four de-
cedents harbored rare variants of uncertain significance 
according to American College of Medical Genetics and 
Genomics criteria in desmosomal-related genes: 1 male 
with a pathogenic DSP variant hosted both missense 
and splice-site variants in DSC2; a previously reported 
rare missense variant was identified in DSC2 was identi-
Table 1. Clinical and Pathological Characteristics Stratified by Circumstances of Death
Characteristics Overall Death During Exertion
Death at Rest/
During Sleep P Value
n (%) 202 83 (41) 105 (52)  
Age at death, y 35.4±13.2, 34.5 32.7±12.5, 29 37.7±13.1, 37 0.01
Male, n (%) 166 (82) 78 (94) 76 (72) <0.001
White, n (%) 182 (90) 74 (89) 96 (91) 0.60
Body weight, median 81.5±17.4, 81
n=131 (65)
81.0±16.9, 80
n=57 (69)
81.0±17.8, 80.55
n=68 (65)
0.99
Diagnosis of cardiomyopathy antemortem, n (%) 15 (7) 1 (1) 13 (12) 0.004
Previous syncope, n (%) 20 (10) 8 (10) 12 (11) 0.69
Asymptomatic status, n (%) 157 (78) 65 (78) 80 (76) 0.86
FH SCD (<35 y old), n (%) 15 (7) 5 (6) 9 (9) 0.58
Macroscopically normal appearance of the heart 
at autopsy, n (%)
40 (20) 18 (22) 20 (19) 0.70
Disease confined to right ventricle, n (%) 26 (13) 11 (13) 14 (13) 0.99
Disease confined to left ventricle, n (%) 35 (17) 15 (18) 19 (18) 0.99
Biventricular disease, n (%) 141 (70) 57 (69) 72 (69) 0.99
Values presented are mean±SD, median, or n (%) as appropriate. P values represent the strength of association between circumstances of 
death and the available clinical or demographic variables. Comparisons are made using appropriate tests on each variable’s nature. Circumstances 
of death were unspecified for 14 of 202 individuals. FH indicates family history; and SCD, sudden cardiac death.
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fied in 1 decedent; and novel missense variants in DSP 
and PKP (variants of uncertain significance) were identi-
fied in 2 individuals also harboring pathogenic variants 
in these genes. All variants of uncertain significance  are 
outlined in Table III in the online-only Data Supplement.
Clinicopathological Correlations
Clinical investigations were available in 10 of the 15 
(67%) decedents with an antemortem diagnosis of 
cardiomyopathy. Seven subjects were diagnosed with 
DCM of which 4 had implantable cardioverter defibril-
lators in situ, and 3 decedents were diagnosed with 
ACM of which one had an implantable cardioverter 
defibrillator. Cardiac MRI had been performed in half 
and showed evidence of LV disease in 4 of 5 (80%). 
Modified Task Force criteria were applied retrospectively 
to all 10 cases. None of the decedents with a clinical 
diagnosis of DCM achieved a definite diagnosis of ACM 
by using Task Force criteria (Table  4). Figure  4 shows 
ECG, CMR, and echocardiogram appearances in an in-
dividual with LV-exclusive ACM diagnosed with DCM 
before death. Of 7 presumptive DCM diagnoses, none 
fulfilled major or minor Task Force criteria for imaging 
(Table IV in the online-only Data Supplement), whereas 
6 (86%) exhibited T-wave inversion in at least one of 
the lateral leads (I, aVL, V5, and V6) and none demon-
strated T-wave inversion in V1 through V3.
After autopsy examination, macroscopic appearanc-
es of the heart were abnormal in all 10 subjects. Post-
mortem genetic testing was undertaken in only a few 
and identified a DSP pathogenic variant in one DCM 
case, and a PKP2 pathogenic variant in an individual 
with ACM.
DISCUSSION
To our knowledge, we report the largest pathological 
series of ACM in SCD using contemporary definitions. 
We demonstrate that comprehensive histopathologic 
evaluation identifies LV involvement in the overwhelm-
ing majority (87%) of individuals experiencing SCD 
Figure 3. Distribution and location of disease involvement in ACM.  
Left, Ventricular disease involvement among all ACM decedents (n=202) Right, Distribution of fibrofatty infiltration among whole hearts referred to pathology 
center (n=120). ACM indicates arrhythmogenic cardiomyopathy; LV, left ventricle; LVAL, LV anterolateral wall; LVPW, LV posterior wall; LVS, LV septum; RV, right 
ventricle; RVAL, RV anterolateral wall; RVOT, RV outflow tract; RVPW, RV posterior wall; and RVS, RV septum. 
Table 2. Analyses of Death During Physical Exertion Among ACM Decedents
Decedents
Univariable Analysis Adjusted Analysis
Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Male 5.95 (2.19–16.19) <0.001 4.58 (1.54–13.68) 0.006
White 0.77 (0.29–2.04) 0.60   
Age at death 0.97 (0.95–0.99) 0.01 0.99 (0.97–1.02) 0.51
Body weight* 1.00 (0.90–1.11) 0.99   
Heart weight† 1.02 (0.99–1.05) 0.16   
Competitive athlete 20.30 (6.84–60.34) <0.001 16.62 (5.39–51.24) <0.001
Left ventricular involvement 1.01 (0.43–2.35) 0.99   
ACM indicates arrhythmogenic cardiomyopathy.
*Per 5-kg increase in weight.
†Per 10-g increase in heart weight.
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from ACM. This appears to be independent of age 
at death, sex, normal macroscopic appearance of the 
heart, and participation in competitive sport.
Clinical Associations and Implications
Although ACM affects both sexes, men are more of-
ten phenotypically affected with a higher mortality rate 
and an increased incidence of cardiac arrest as the ini-
tial manifestation.21,22 These observations are consistent 
with our cohort, which was mainly male (82%). Fur-
thermore, although death during physical exertion is 
well described,15 52% of deaths in our study occurred 
at rest or during sleep. Syncope is also a common pre-
senting symptom and marker of SCD risk. A quarter of 
a US cohort of patients with ACM (N=100) had a his-
tory of syncope,23 and an Italian registry of 301 patients 
with ACM reported that syncope was associated with 
a 3-fold increased risk of life-threatening arrhythmic 
events during follow-up.24 Nonetheless, most subjects 
in our study (78%) did not report any cardiac symptoms 
before presenting with SCD, and only 10% had experi-
enced some form of syncope.
More than half of our decedents diagnosed with car-
diomyopathy in life were labeled as DCM, but showed 
pathological features of ACM at autopsy. The overlap 
between DCM and ACM may present several diagnos-
tic challenges as reflected in the finding that none of 
our decedents with an antemortem diagnosis of DCM 
fulfilled current Task Force criteria for a definite diag-
nosis of ACM. Among the antemortem DCM cohort, 
6 (86%) exhibited T-wave inversion in at least one of 
the lateral leads: I, aVL, V5, and V6; none demonstrated 
T-wave inversion in V1 through V3. This highlights the 
phenotypic spectrum of ACM and the potential for bi-
ventricular disease to evade clinical diagnosis and sub-
sequent risk management. We also identified a family 
history of young SCD (<35 years old) in 7% of the co-
hort, none of whom were diagnosed with cardiomyop-
athy during life. Guidelines recommend comprehensive 
family evaluation in this setting and may have led to the 
recognition of risk before death.25
Myocardial Involvement at Autopsy
An early pathological study of 30 ACM hearts revealed 
LV involvement in 47% of their cohort.8 Patchy inflam-
matory infiltrates were also detected in 20 (67%) cases, 
a finding that was not replicated during histological 
examination of our study group. A later study of 42 
cases showed macroscopic or microscopic features of 
LV disease in 76%, with a predilection for the septum 
and free wall (posteroseptal and posterolateral re-
gions).9 In keeping with this and other previous studies, 
the posterobasal wall was the most common location 
of LV fibrofatty infiltration (68%) in our group. More 
recently, LV histological abnormalities were found in a 
lower proportion (32%) of 200 SCD cases attributed to 
ACM.10 However, fatty infiltration of the RV was con-
sidered pathological in this study, even in the absence 
of fibrosis. Our observations suggest that fatty infiltra-
tion of the RV should not be considered diagnostic for 
ACM. Our study also reports LV histopathologic involve-
ment in a much higher proportion of decedents with 
ACM (87%). The role of inflammation in ACM has yet 
to be fully resolved. The lack of myocardial inflamma-
tory infiltrates detected among our cohort is contrary to 
earlier assertions linking inflammation to the severity of 
outcome in ACM.26
Correlation With Imaging Studies
The natural history of LV involvement in ACM is poorly 
understood. Our finding that LV involvement was not 
associated with age at death or macroscopic appear-
ance of the heart at autopsy corroborates imaging stud-
Table 3. Overview of Pathogenic Variants Identified From Postmortem Genetic Testing
Case ID
Age at 
Death
Circumstances 
of Death
Antemortem 
Diagnosis Pathology Gene cDNA Change
ExAC 
MAF ACMG
Case 1 
White male
37 Died in sleep ACM Right ventricular 
ACM
PKP2 c.2198_2202delACACC 0 Pathogenic
PVS1; PM2; PP3
Case 2 
White male
20 Died during 
exertion
None Right ventricular 
ACM
PKP2 c.253_256delGAGT 0 Pathogenic
PVS1; PM2; PP3
Case 3 
White female
26 Died at rest DCM Biventricular ACM DSP c.4395T>G 0 Pathogenic
PVS1; PM2; PP3
Case 4 
White male
28 Died at rest DCM Biventricular ACM DSP c.5269C>T 0 Pathogenic
PVS1; PM2; PP3
Case 5 
White male athlete
20 Died during 
exertion
None Biventricular ACM TMEM43 c.1073C>T 0 Pathogenic 
PS1; PM2; PM7; PP3
Case 6 
White male
45 Died at rest None Biventricular ACM TMEM43 c.1073C>T 0 Pathogenic 
PS1; PM2; PM7; PP3
ACM indicates arrhythmogenic cardiomyopathy; ACMG, American College of Medical Genetics and Genomics; cDNA, complementary DNA; DCM, dilated 
cardiomyopathy; DSP, desmoplakin; ExAC, Exome Aggregation Consortium; MAF, minor allele frequency; PKP2, plakophilin-2; PM, pathogenic moderate; PP, 
pathogenic supporting; PS, pathogenic strong; PVS, pathogenic very strong;  and TMEM43, transmembrane protein 43. 
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Table 4. Clinicopathological Correlations Among ACM Decedents Diagnosed With Cardiomyopathy Antemortem
Case
Antemortem 
Diagnosis
Age 
at 
Death
Circumstances 
of Death
Application of Modified TFC (2010)
TFC 
2010
Major*
TFC 
2010 
Minor*
TFC 2010 
Diagnostic 
Certainty
Pathological 
Diagnosis
Depolarization/
Conduction Repolarization
Ventricular 
Arrhythmias Imaging
Family 
History
A ACM 37 Died at rest Minor criterion: 
SAECG, 3 
abnormal 
parameters
Major 
criterion: 
Negative T 
waves in V1, 
V2, V3, and V4
Minor criteria:
(1) NSVT with 
unknown axis
(2) >500 
PVCs/24 h
Major 
criterion 
(CMR 
and 
Echo)
None 2 2 Definite BiV ACM
B ACM (ICD in 
situ)
44 Died at rest None None.
V paced 
rhythm
Minor 
criterion:
(1) Sustained 
VT with 
unknown axis
Major 
criterion 
(CMR 
and 
Echo)
None 1 1 Borderline BiV ACM
C ACM 37 Died in sleep None None Major 
criterion:
(1) NSVT with 
LBBB and 
superior axis
Minor 
criterion:
(2) >500 
PVCs/24 h
Minor 
criterion 
(CMR)
None 1 1 Borderline RV ACM
PKP2†
D DCM 49 Died during 
exertion
Minor criterion: 
Terminal 
activation 
duration of QRS 
≥55 ms in V1
Minor 
criterion: 
Negative T 
waves in V4, 
V5, and V6
Minor 
criterion:
(1) >500 
PVCs/24 h
None
(CMR 
and 
Echo)
None 0 3 Borderline LV ACM
E DCM 29 Died at rest None Minor 
criterion:
Negative T 
waves in V4, 
V5, and V6
Major 
criterion:
(1) NSVT with 
LBBB and 
superior axis
Minor 
criterion:
(2) >500 
PVCs/24 h
None
(CMR 
and 
Echo)
None 1 1 Borderline BiV ACM
F DCM (ICD in 
situ)
48 Died at rest None Minor 
criterion:
Negative T 
waves in V4, 
V5, and V6
Minor 
criterion:
NSVT with 
unknown axis
None 
(Echo)
None 0 2 Possible BiV ACM
G DCM (ICD in 
situ)
35 Died at rest None Minor 
criterion:
Negative T 
waves in V5 
and V6
Minor 
criterion:
(1) NSVT with 
unknown axis
None 
(Echo)
None 0 2 Possible BiV ACM
H DCM (ICD in 
situ)
26 Died at rest None Minor 
criterion: 
Negative T 
waves in V4, 
V5, and V6
Minor 
criterion:
(1) Sustained 
VT with 
unknown axis
None 
(Echo)
None 0 2 Possible BiV ACM
DSP†
I DCM (ICD in 
situ)
41 Died at rest None None.
A-V paced 
rhythm
Minor 
criterion:
(1) Sustained 
VT with 
unknown axis
None 
(Echo)
None 0 1 N/A BiV ACM
J DCM 56 Died in sleep None Minor 
criterion:
Negative T 
waves in V4 
and V5
None None 
(Echo)
None 0 1 N/A LV ACM
ACM indicates arrhythmogenic cardiomyopathy; A-V, atrial and ventricular; BiV, biventricular; CMR, cardiovascular magnetic resonance; DCM, dilated 
cardiomyopathy; DSP, desmoplakin; Echo, echocardiography; ICD, implantable cardioverter defibrillator; LBBB, left bundle-branch block; LV, left ventricular;  RV, right 
ventricular; NSVT, nonsustained ventricular tachycardia; PKP2, plakophilin-2; PVCs, premature ventricular contractions; SAECG, signal-averaged ECG; TFC, Task Force 
Criteria (2010)6; and V, ventricular.
*Task Force Criteria attained from different categories.
†Pathogenic variant detected in gene following postmortem genetic testing.
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ies that suggest LV involvement may occur at an early 
stage.27 Ghannudi et al28 evaluated 21 patients with 
ACM and found that 52% had LV involvement on CMR. 
The degree of RV impairment was similar between those 
with isolated RV involvement and disease affecting the 
LV. Rastegar and colleagues29 also studied 78 ACM mu-
tation carriers of whom 38 had structural abnormalities 
on CMR, including the LV in 55%. The higher propor-
tion of cases with LV involvement in our cohort may re-
flect a greater sensitivity of histopathology for fibrosis.
Competitive Sport
The link between athletic activity and SCD risk in patients 
with ACM is widely acknowledged.30 A previous study 
found that participation in competitive sport was associ-
ated with a 2-fold increased risk of ventricular arrhyth-
mia and SCD in ACM, but recreational sport followed a 
more benign course.31 Data from a prospective multina-
tional registry of athletes with implantable cardioverter 
defibrillators also identified ACM as the only diagnosis 
associated with appropriate shocks during competitive 
sport.32 Current guidelines recommend against partici-
pation in competitive and endurance sport among in-
dividuals meeting Task Force criteria.33 Our data show 
that most competitive athletes who died with ACM 
were engaged in sports with a maximum dynamic com-
ponent (ie, requiring the highest cardiac output), and 
most (90%) of these deaths occurred during physical 
exertion. We found no difference in either RV-exclusive 
disease or LV involvement between athletes and non-
athletes, suggesting that exercise-induced remodeling 
alone is insufficient to lead to the ACM phenotype.
Genetic Evaluation and Implications
To our knowledge, there have been no published stud-
ies evaluating the utility of postmortem genetic testing 
in ACM. Diagnostic yield may be influenced by sever-
al factors, such as disease presentation, family history, 
and geographic region.34 Our use of a stringent minor 
allele frequency threshold and application of American 
Figure 4. A case of LV-dominant ACM.  
A, Histological slide (Picrosirius red stain) demonstrating myocyte degeneration and fibrofatty infiltration within the posterolateral wall of the LV (extending trans-
murally). B, 12-lead ECG showing first-degree AV block, inferolateral T-wave inversion (arrows), and low-voltage limb lead QRS complexes, prolonged terminal ac-
tivation duration in V1, and ventricular bigeminy with fragmented, broad, ectopics of RBBB morphology and superior axis (arrow). C and D, Delayed-enhancement 
CMR images illustrating extensive LV delayed enhancement, including near transmural enhancement of the lateral wall and midwall enhancement of the anterior 
wall. E, Parasternal long-axis view (echocardiography) showing severe LV dilatation (left ventricular end-diastolic dimension, 71 mm). ACM indicates arrhythmo-
genic cardiomyopathy; AV, atrioventricular; CMR, cardiovascular magnetic resonance; LV, left ventricle; and RBBB, right bundle branch block.
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College of Medical Genetics and Genomics criteria may 
have resulted in a more conservative yield in comparison 
with previous genetic studies.34,35 Among decedents un-
heralded with cardiac disease, none had a reported fam-
ily history of ACM. The only pathogenic variants identi-
fied in this group were in TMEM43 and PKP2, the same 
missense variant being identified in both (unrelated) 
TMEM43 subjects. This variant had previously been re-
ported in multiple ACM families internationally, is highly 
penetrant and has strong evidence for pathogenicity.36 
Both probands exhibited histopathologic involvement of 
the LV, consistent with previous data on the mutation, 
which is associated with a particularly malignant form of 
ACM (Arrhythmogenic Right Ventricular Cardiomyopa-
thy Type 5). DSP is also highly penetrant and associated 
with LV involvement and higher risk, especially truncating 
variants.37,38 Two subjects hosted truncating pathogenic 
DSP variants, and both had previous diagnoses of DCM.
Implications for the Pathologist and 
Clinician
We demonstrated that 20% of ACM cases were mac-
roscopically normal on initial inspection, regardless of LV 
involvement. Our findings are in line with earlier stud-
ies that recognize a concealed phase in ACM, where 
SCD may occur in the absence of overt structural abnor-
malities.39 This reinforces the importance of histological 
analysis of hearts in all cases of SCD. Moreover, previous 
reports have described sudden death occurring in PKP2 
mutation carriers exhibiting structurally normal hearts at 
autopsy16,40; this may suggest a propensity for malignant 
arrhythmia in those with a pure electric phenotype.
In 17% of our cases, fibrofatty infiltration was identified 
exclusively within the LV, consistent with the previously de-
scribed entity of LV-dominant ACM.13 LV-dominant ACM 
may manifest clinically with inferolateral T-wave inversion 
on the 12-lead ECG, arrhythmias of LV origin, and sugges-
tive appearances on cardiac imaging. Thus, the absence 
of RV structural abnormality may lead to poor recognition 
of nonclassical disease utilizing current diagnostic criteria. 
Moreover, the significant minority of ACM SCD cases with 
LV-exclusive disease support inclusion of LV pathological 
and clinical markers in future revision of Task Force criteria.
Study Limitations
This study relied on referral of SCD cases to an expert 
cardiac pathology center; therefore, there may be an el-
ement of referral bias because pathologists may choose 
to refer more challenging cases and potentially a higher 
proportion of cases with LV involvement. In 41% of 
cases, the whole heart was not sent to the center for 
analysis and macroscopic appearances of the heart 
were noted by the referring pathologist. Consequently, 
sampling technique may differ according to local proto-
cols. However, tissue blocks from both ventricles were 
received in each case and histological diagnostic criteria 
consistently applied. Retrospective review of clinical in-
formation, competitive sports participation, and family 
member interviews could be subject to recall bias and 
may have underestimated the true extent of symptoms 
experienced in life that may otherwise have not been 
documented. Finally, although genetic testing was per-
formed on all possible individuals with retained DNA 
for molecular autopsy, the group with genetic results 
is small, so the inference of genotype-mediated risk is 
inappropriate. A larger genetic testing uptake in the 
cohort would facilitate important genotype-phenotype 
correlations and assessment of genetic yield, which 
would be an important area worthy of future research.
Conclusions
Most ACM-related SCDs occurred without preceding 
antemortem symptoms or relevant family history. Exer-
cise-related SCD was observed in the majority of com-
petitive athletes, with competitive sport participation 
conveying significantly increased odds of death during 
physical exertion. A fifth of cases demonstrated a mac-
roscopically normal heart, emphasizing the importance 
of histopathologic evaluation in cardiac autopsy. LV in-
volvement was present in the great majority of cases, 
with 17% exhibiting disease exclusive to the LV. Our 
study supports inclusion of LV structural involvement in 
future revision of Task Force diagnostic criteria.
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